Docosahexaenoic Acid (DHA) Supplementation in Amblyopia
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This study evaluates the addition of docosahexaenoic acid (DHA) to eye patching in the
treatment of residual amblyopia in children ages 3 to 18 years old. Two thirds of
participants will receive DHA along with eye patching, while one third of participants will
receive a placebo along with eye patching.